Kottschade L.A. et al. (2013) studied the effectiveness of chemotherapy (temozolomide versus nanoparticle albumin-bound-paclitaxel and carboplatin) in combination with vascular endothelial growth factor (VEGF) inhibition (bevacizumab), in patients with unresectable stage IV melanoma [84]. The gene discussed is VEGFA; the disease is melanoma.